![[ Fidia Farmaceutici s.p.a. ]](../media/logo.gif "[ Fidia Farmaceutici s.p.a. ]"){kind=logo} |
![[ Riga menù ]](../media/riga.gif "[ Riga menù ]"){kind=small}
![[ Banner Istituzionale ]](../media/istituzionale.gif "[ Banner Istituzionale ]") |
![[ Barra Menù ]](../media/barra.gif "[ Barra Menù ]"){kind=small} |
![[ Linea verticale ]](../media/separatore.gif "[ Linea verticale ]"){kind=small} |
![[ Riga dot ]](../media/rigadot.gif "[ Riga dot ]"){kind=small} |
![[ News & Events ]](../media/titevents.gif "[ News & Events ]")
|
|
Genzyme's EP patent has been finally revoked in its entirety by the EPO Board of Appeal 18/11/2008 - Company news |
|
The U.S. FDA has accepted the IND application for the development of a 140mg Diclofenac Sodium Matrix Patch for the topical treatment of acute pain 17/11/2008 - Company news |
© 2000 - 2009 Fidia Farmaceutici s.p.a. Tutti i diritti riservati
Cap. Soc. € 36.120.000 int. vers. - C.C.I.A.A. PD n. 80793 - Iscr. Reg. Imp. PD - Cod. Fisc. e P. IVA 00204260285
e-mail: info@fidiapharma.it
![[ News & Events ]](../media/titevents1.gif "[ News & Events ]"){kind=small}
|
|
| Home | News & Events | |
